Q2 2022 AVITA Medical Inc Earnings Call
You.
The conference will begin shortly. To raise your hand during Q&A, you can dial star 11. The conference will begin shortly. To raise your hand during Q&A, you can dial star 11.
Hello, thank you for standing by and welcome to the Avita Medical Inc. 2nd Quarter 2022 Earnings Conference call. At this time, all participants are in a listen-only mode. After the speaker presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 1-1 on your telephone. Please be advised that today's conference may be recorded. I would now like to hand the conference over to your speaker today, Caroline Corner. Please go ahead.
Thank you, operator. Welcome to Aveda Medical's second quarter 2022 earnings call. Joining me on today's call are Dr. Mike Perry, Chief Executive Officer, and Michael Holder, Chief Financial Officer. Thank you for joining us today.
This call will include forward-looking statements within the meaning of the Private Security Litigation Reform Act of 1995. All statements made on this call that do not relate to matters of historical fact should be considered forward-looking statements, including statements regarding the markets in which Avita Medical operates, trends, demands, and expectations for its products and technology, its expected financial performance, expenses, and position in the market, and the impact of COVID-19 on its operations and its customers' operations.
These statements are neither promises nor guarantees and involve known and unknown risks and uncertainties that could cause actual results, performance, or achievements to differ materially from any results, performance, or achievements expressed or implied by the forward-looking statements. The scale oxays of these statements clearly show that they do not indicate the values
Please review Avida Medical's most recent filings with the SEC, particularly the risk factors described in Avida Medical's S3 and 10K filings, and in Avida Medical's quarterly report on Form 10Q for the second quarter ended June 30, 2022, for additional information.
Any forward-looking statements provided during this call, including projections for future performance, are based on management's expectations as of today. Aveda Medical undertakes no obligation to update these statements except as required by applicable law.
Avida Medical's press release for the second quarter of 2022 results is available on the website www.avitamedical.com under the investors section and includes additional details about its financial results.
Avida Medical's website also has the latest SEC filings, which you are encouraged to review.
A recording of today's call will be available on the VITA Medical's website by 5 p.m. Pacific time today.
Now I'd like to turn the call over to Mike for his comments and second quarter 2022 business highlights.
Thank you, Caroline, and thank you everyone for joining us today.
We continued to deliver strong growth in our top-line revenue this quarter, and we are pleased to report record commercial resale revenues, which exclude BARDA revenue of $8.2 million compared to $6.7 million, a 23% increase over the same quarter last year.
Our commercial revenue was $15.7 million in the half year ending June 30, 2022, an increase of $4.4 million or 39% compared to $11.3 million in the corresponding period in the prior year.
In the quarter, we achieved greater penetration in a larger base of accounts, leading to an increase in overall burn cases treated with resale.
With ongoing improvement in access to burn centers and in-person meetings, we were able to resume our commercial activities in the new normal operating environment.
Our commercial team increased their field training cadence to reach over 300 burn care providers each month, up from approximately 200 per month in the first quarter. In addition, we are continuing to conduct webinars and summits that are now in person to further broaden our reach.
An increase in field training coupled with case support designed to help alleviate staffing constraints has allowed us to broaden provider adoption, deeper penetration, and ultimately increased order size.
We began selling the ease of use resell device to our larger accounts this quarter, which is resonating well, particularly with those customers who are experiencing ongoing staffing challenges that I just mentioned.
We have shipped the new device in a phased release to approximately a quarter of our accounts.
Turning now to the outpatient market, we initiated our limited launch in March. As we expand into new indications, our outpatient market will become a larger portion of our addressable market and an increasingly important patient population supporting our continued growth.
While the bulk of burn procedures are inpatient, we expect that outpatient treatment will comprise our core soft tissue market. As such, we are working to familiarize centres with outpatient care pathways, coding and coverage.
Relative to Japan, we along with our partner Cosmotec completed our first training and evaluation cases in Japan during the quarter.
As I mentioned in our last call, discussions are ongoing with the Japanese authorities regarding reimbursement and pricing, which we anticipate will wrap up later this year.
I'd like to highlight a recent media story in which a 12-year-old homeschooled student's science experiment exploded, resulting in second and third degree burns to over 50% of his body. In addition to the young student, his mother sustained second and third degree burns while saving her son's life.
Both the boy and his mother have been undergoing resale treatments at the Joseph M. Still Burn Center of Doctors' Hospital in Augusta, Georgia, which is the largest burn care facility in the United States and one of our largest customers.
We are inspired by the burn community, which has been uplifting the family during this crisis, and we are encouraged by both the mother and the son's recovery thus far.
Moving on now to our pipeline indications, we made solid progress in our soft tissue reconstruction and stable vitiligo trials.
We just released top-line data for our soft tissue reconstruction trial.
The study had co-primary endpoints based on pairwise comparisons where each subject received both resale used in combination with widely meshed skin grafting and the control treatment of conventional skin grafting.
One endpoint had hypothesis of superiority for donor skin sparing, and the other co-primary endpoint had a hypothesis of non-inferiority for healing.
Resell showed statistically superior donor skin sparing versus the conventional autographing standard of care control, thereby achieving the end point.
While comparable healing was observed between resell and control,
pre-specified statistical non-inferiority was not met. Nonetheless, the statistically significant donor sparing and comparability in an observed healing along with the established safety record of ReCell together point to a favourable benefit-risk profile. As such, we will proceed as planned with PMA submission.
for both the soft tissue and vitiligo indications later in 2022, with FDA approvals anticipated in the second half of 2023.
As I mentioned previously, once approved in soft tissue reconstruction, we expect to initially leverage our installed base of burn centers and our existing infrastructure to launch the Riesl system into our burn centers that are co-located with level 1 and level 2 trauma centers.
From there, we plan to grow into another 200 to 250 high-volume trauma centers, which do some burn cases as well, and we'll update you on our plans here in future calls.
Notably, trauma centers will be able to use the existing reimbursement codes currently being used in the burn setting.
We are excited to deploy what we've learned in burn care to efficiently and effectively address the soft tissue trauma opportunity.
Turning now to vitiligo, and as we stated in previous calls, this is a skin disorder characterized by depigmented areas of skin that appear as white spots or patches and which are primarily attributed to an underlying autoimmune disorder in the patient.
There are an estimated 100 million sufferers of the Delilah worldwide, including up to 6.5 million Americans.
With recent completion of patients' six-month follow-ups for our vitiligo clinical trial, we expect top-line data followed by PMA submission during the second half of 2022, with FDA premarket approval and commercial introduction anticipated prior to the end of 2023.
We recognize that our current resell product involves hands-on preparation of the cell suspension by physicians and or their supporting staff. To make the best use of physician and support personnel's time in the dermatologist's office to address our Vitiligo opportunity, we are developing an automated resell device.
We are encouraged by the FDA's recent approval of a topical JAK inhibitor, which we believe will further drive vitiligo disease awareness in this very large market that has limited effective treatment options.
Over time, we anticipate multiple product entrants to this compelling opportunity.
We believe the strong safety record of ReCell and the one and done nature of the associated treatment procedure will be differentiated as well as medically and commercially important.
We've been working diligently on vitiligo pre-commercialization activities.
Avida has attended nine dermatology conferences since January of this year. At these conferences, over 25 sessions have featured vitiligo, a marked increase year over year as JAK inhibitors and ReCell have stimulated interest in vitiligo treatments.
Importantly, Riesl received numerous mentions in these sessions.
With that, I'd now like to remind you of our strategic growth drivers.
We are keenly focused on driving healthcare provider engagement through education, maintaining our recent momentum in burns.
The fall conference season is just ahead and we are excited for continued in-person conversations.
Second, we anticipate submission of PMA supplements by the end of 2022 for both soft tissue reconstruction and vitiligo indications, and we continue to plan to enter those markets in the second half of 2023.
Lastly, and turning to a longer term growth driver, our pilot work in establishing Resell within the outpatient setting continues, where we anticipate the future bulk of soft tissue trauma cases.
In summary, we are executing on our business objectives and have successfully achieved several key milestones this year.
I'm encouraged by our commercial teams performance driving advanced practice training and keeping resale front and center in the minds of burn care practitioners.
I look forward to updating you later this year and our continued programs in our exciting pipeline indications.
With that, I will now turn it over to Michael for details on our financial performance in the quarter. Michael? …
Thank you Mike. Relative to our three months into June 30th, 2022 financial results.
Our commercial revenue, which excludes BARDA revenue, was $8.2 million for the three months into June 30, 2022, an increase of $1.5 million, or 23%, compared to $6.7 million in the corresponding period in the prior year.
Total revenue, which includes BARDA revenue, was $8.3 million in the current year compared to $10.3 million in the corresponding period in the prior year, which included $3.6 million in BARDA-related revenue that resulted from our delivery of units to manage inventory for BARDA for emergency response preparedness.
The growth in commercial revenues was largely driven by an increase in the number of customers ordering as well as the average order size for those customers.
Gross profit margin improved by 3% to 83% compared to the corresponding period in the prior year.
Total operating expenses increased by 3% to $13.9 million compared to $13.4 million in the corresponding period in the prior year.
The increase in operating expenses is primarily attributable to higher compensation costs.
sales commissions, and professional fees partially offset by lower clinical trial related expenses.
Higher compensation costs resulted from an expansion of our commercial team, while higher commissions were driven by an increase in revenues.
Higher professional fees were driven by an increase in pre-commercialization activities for reset launches in soft tissue reconstruction in vitiligo.
Clinical trial expenses incurred in our soft tissue and vitiligo trials were lower during the period as trial participants were in the follow-up phase, which is less costly than the earlier recruitment and treatment phases.
Net loss increased by 33% or $1.5 million to $6.3 million or $0.25 per share compared to a net loss of $4.7 million or $0.19 per share in the corresponding period of the prior year.
adjusted EBITDA loss increased by 51% or 1.6 million to 4.7 million over the 3.1 million recognized in the corresponding period in the prior year.
relative to our six-month end of June 30th, 2022 financial results.
Our commercial revenue, which excludes barter revenue, was $15.7 million in the six months end of June 30, 2022, an increase of $4.4 million, or 39%, compared to $11.3 million in the corresponding period in the prior year.
Total revenue, which includes BARDA revenue, was $15.9 million in the current year compared to $19.1 million in the corresponding period in the prior year, which included $7.7 million in BARDA-related revenue that resulted from our delivery of units to manage inventory for BARDA for emergency response preparedness.
The growth in commercial revenues was largely driven by an increase in the number of customers ordering as well as the average order size for those customers.
Growth profit margin improved by 2% to 80% compared to the corresponding period in the prior year.
Total operating expenses increased by 12% to $29.9 million compared to $26.6 million in the corresponding period in the prior year. The increase in operating expenses is primarily attributable to higher compensation costs and professional fees partially offset by lower clinical trial related expenses.
Higher compensation costs were primarily a result of increased share-based compensation expenses due to certain performance milestones being met, higher commissions driven by an increase in revenues and an expansion of our commercial team.
Increased professional fees were driven by an increase in pre-commercialization costs for resale launches and soft tissue reconstruction and Dentaligo.
Research and development expenses were lower relative to the prior year, during which higher costs were incurred related to recruitment and treatment for the soft tissue and Dentaligo clinical trials.
Net loss increased by 47%, or 5 million to 15.7 million, or 63 cent per share compared to a net loss of 10.7 million, or 45 cent per share in the corresponding period in the prior year.
adjusted EBITDA loss increased by 46 percent or 3.5 million to 11.1 million over the 7.6 million recognized in the corresponding period in the prior year.
A table reconciling non-GAAP measures is included in the related press release for reference.
Turning to guidance, commercial revenues in calendar year 2022 are projected to be approximately $30 million, excluding barter revenues, which represents a 20% increase year over year.
We project barter revenues of approximately $0.3 million in calendar year 2022 as compared to $7.9 million in calendar year 2021 since we completed delivery of resale units into the national stockpile in 2021.
With that, we thank you for your attention, and now I will turn the call back over to the operator for your questions.
Thank you. As a reminder, to ask a question, you will need to press star 1 1 on your telephone. Please stand by while we compile the Q&A roster.
Our first question comes from Joshua Jennings with Cowan. You may proceed.
Hi, good afternoon and congratulations on the strong
I was hoping to focus on the pipeline and wanted to, Mike, just ask about the soft tissue top line data. I took a couple weights off since I didn't have to use them and I left,organisms, a series
understand that there was comparable healing in that one of the co-primary endpoints but maybe you could just help us.
understanding, give a little bit more detail on why you think that the not hitting statistical but non-inferiority can be overcome and just any details you can share on the comparability and why you're confident that the submission is approvable. Sure, Josh. Thanks for the question. Really, the aim of the study was to show that resale treatment.
in soft tissue injury results in equivalent healing while using less donor skin.
So, we had co-primary endpoints, first endpoint, donor sparing, donor skin sparing was achieved at P less than 0.001. So that one's clean. The non-inferiority healing was achieved at P equals 0.048, which is equivalent to P less than 0.08. So, one lifetime chemistry trial where we prepared for???????? spread at P. When we described each Seq, there was another study that consisted of 3,500 side effects during each of therief allow us to prevent reformation with positiveif, without sustaining
0.05, but was not achieved at the pre-specified statistical significance of p less than 0.025.
Basically what you're looking at is a 95% confidence interval around a two-sided t-test.
for a 0.025. If you're looking at a 95% confidence interval around a one-sided T-test, which often FDA accepts.
for approval, then you've got the 0.025 on a one sided t-test.
So based upon that, as well as based upon the benefit risk analysis.
rather than just simple endpoint analysis that the FDA uses for Class III medical devices. We're very confident that, based upon the results of this pivotal study, that we're going to be able to file our PMA on our original timeline, and we're also strong in our conviction that we'll receive FDA approval.
Did that answer your question, Josh? It did. And that's very helpful. Thanks, Mike. And just any comment on just in terms of the safety events or adverse events in either the study group or the control group? I'm assuming you're not going to call them out that there really was no difference. But just wanted to clarify that. Yeah, certainly. We did look at adverse events, of course. And there were no differences between the control and the treated arm.
but just wondering if just in general, either at Vitiligo or any other channels, whether there's any partnership opportunities that you're pursuing for commercialization, either in the burn space or the dermatology space or the trauma space. Thanks for taking all the questions.
Thanks, Josh. Answer the first question. First, on vitiligo, we do have all of the patients completed their six-month endpoints, and we're looking at those data now. So we're anticipating that we will be releasing those data, top-line data, shortly.
within the coming weeks. And relative to partnerships, either in Burns or in Vitiligo, at this time, we are still planning for a go it alone strategy. And that said, we're still going to be opportunistic relative to partnership opportunities.
Especially if they're going to be accretive to our earnings and will look better overall for our revenue slopes and increasing revenues over time.
Thanks so much. Appreciate it, Mike. Thanks, Josh.
Thank you. One moment for questions.
Our next question comes from Matthew O'Brien with Piper Sandler. You may proceed.
Hey, this is Phil on format. Thanks for taking my questions and just to start here on the guide to the back half of the year.
how your core business did in the first half versus what you're implying in the second half, which is, you know, slow down. You know, really you're guiding to about 3% growth for the second half.
you know, while you're in this position. You know, any insight into what you see that gives you pause to maybe bring up that guidance a little bit? Thank you. We'll see you a little bit more after.
Sure. Thanks for the question, Matt. We wanted to stick with a number that we're confident in and we are confident in approximately 30 million. The reasons for that, given what we have in our first half of the year, are a combination of really seasonality with the business.
potential supply chain issues, you know, macroeconomics, the staffing, you know, issues that are prevalent in the hospitals, as well as potential COVID flares which could slow things down. So, you know, really with that, we're just holding tight in what we're confident of.
Makes sense. Thank you. And just one more for me. On those labor shortages, which are ongoing and have been pervasive in the industry, are you seeing any improvements on that front? Any line of sight into when it'll be less of a headwind, maybe back half this year or sometime next year? And then if you could kind of reiterate how your new ease of use system is kind of improving that as well, that'd be great.
Sure. Thanks again, Matt. Relative to the labor shortages, we are not seeing an improvement there. The good news is it seems to have settled into at least a level amount of, it's primarily the nursing shortage if we really want to.
pinpoint it. And our trainings have increased from 200 a month to 300 a month in order to keep up with the shortages. And we feel that that's additional opportunity for us to get in with the surgeons. And, you know, we're turning a difficult situation into an opportunity for Avida.
And so far as our ease of use device, we have launched that. That's definitely a leg up that we have relative to the staffing shortages in the hospitals. And that's rolling out well, being well received. And we continue to have confidence that this will Onto dads this summer,
help us and we'll move the adoption of ReCell further.
Awesome, thanks for the color and I'll hop back in queue.
back in queue. Thanks, Matt.
Thank you. One moment for questions.
Our next question comes from Ryan Zimmerman with BTIG. You may proceed.
Hey, Mike and Michael, thanks for taking the questions. Congrats on the record revenue this quarter. I want to start actually on the burn market though for a moment and just talk about, you know, you referred to some deeper account penetration this quarter. And Mike, if you just talk about kind of, you know, are you seeing lower TBSA? Are you seeing higher TBSA? Are you seeing customers stock up ahead of their push into outpatient?
Just appreciate the color on the metrics. The step up in utilization amongst surgeons by our math was pretty meaningful quarter over quarter.
Yeah, we in general – well, thanks for the question, Ryan. In general, what we're seeing that our top customers are stable and we're getting a broader group of customers utilizing the resale device, which is exactly what we want. Relative to size, we're not seeing a substantial increase in the number of customers that are using the resale device. So, we're seeing a substantial increase in the number of customers that are using the resale device.
reduction in the size of burns that are being treated. That said, the trend is going toward smaller burns.
You know, it's you know, when you start looking at the TBSA it's it's difficult
I would say no huge change would be correct.
Okay, I appreciate that. That's helpful, caller. We're good now.
Turning to Japan for a moment, you talked about reimbursement and pricing by year end 2022. What line of sight do you have with CosmoTech in terms of certainty around that from the Japanese PMDA? And how should we think about what we can expect in terms of reimbursement in Japan and whether that's sufficient to drive adoption? And the second part of that is, how do you think about adoption?
you know, going into 23 in Japan, assuming you can pick up what you need there? Sure. Thanks again for that question, Ryan. For Japan, we're, you know, hearing very good things from our partner Cosmotec. And we do anticipate that we will have reimbursement from the MHLW. Discussions are ongoing.
And we're still optimistic, if not confident, that we'll have reimbursement by the end of this calendar year.
I guess relative to the US, pricing is usually favorable relative to Europe or other countries. But our situation is that based upon the reimbursed price we've negotiated that we'll receive 40% of that reimbursed price.
And our partners are going with a staged launch in Japan. And they've actually already started basically teaching with our key opinion leaders in Japan. And we've shipped a number of kits. But we won't be able to go commercial until we've got that MHLW pricing.
Fair enough, and if I could speak one last one in and I'll hop back in queue. Gross margins, really nice this quarter. Michael, can you maintain this kind of level of gross margin going forward? It's a nice step up from Q1. the
Thank you, Brian , for your question.
We do look to maintain these margins.
Here at the low 80% level. So, we should be good with that going forward for the for the foreseeable future.
Yeah, to add to that, Ryan, we're continuing to working on continued cost savings in the context of shipping, which will sustain or increase our gross margins.
Thank you.
Thank you. I would now like to turn the call back over to Mike Perry and Michael Holder for any closing remarks.
Well, I want to thank everybody for joining us today in our quarterly meeting. We're excited, very excited about the future and, you know, basically near-term milestones of submitting PMAs for both vitiligo and soft tissue reconstruction by the end of this calendar year with approvals in the second half of 2023.
With that, again, thank you for your kind attention, and let's close the meeting.
Thank you. This concludes today's conference call. Thank you for participating. You may now disconnect.
conference will begin shortly. To raise your hand during Q&A, you can dial star 1-1.
We.